ABSTRACT
Canagliflozin (CAN) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus. There is a little information about its effect on the cholinergic system that proposed mechanism for memory improvement occurring by SGLT2 drugs. This study aimed to estimate the effect of CAN as compared to galantamine (GAL) treatments for two weeks on scopolamine hydrobromide (SCO)-induced memory dysfunction in experimental rats. Animals divided into six groups; control (CON), CAN, GAL, SCO, SCO + CAN and SCO + GAL. Results indicated significant decrease in body weights of the CAN groups as compared to control values. Moreover, in the SCO + CAN and SCO + GAL the number of arm entry and number of correct alternation in Y maze task increased and showed improvement in the water maze task, acetylcholinesterase (AChE) activities decreased significantly, while monoamines levels significantly increased compared with the SCO group values. Results also recorded acetylcholine M1 receptor (M1 mAChR) in SCO + CAN or SCO + GAL groups in comparison with the SCO group. The study suggested that canagliflozin might improve memory dysfunction induced by scopolamine hydrobromide via cholinergic and monoamines system.
Subject(s)
Canagliflozin/therapeutic use , Hypoglycemic Agents/therapeutic use , Memory Disorders/chemically induced , Memory Disorders/prevention & control , Memory/drug effects , Scopolamine , Acetylcholinesterase/metabolism , Animals , Galantamine , Hippocampus/drug effects , Hippocampus/metabolism , Male , Maze Learning/drug effects , Memory Disorders/metabolism , Rats , Rats, WistarABSTRACT
BACKGROUND: The rapid economic development in the Arabian Gulf has resulted in lifestyle changes that have increased the prevalence of obesity and type 2 diabetes, with the greatest increases observed in Kuwait. Dyslipidemia and diabetes are risk factors for disruptions in cortical neurotransmitter homeostasis. This study investigated the effect of the antidiabetic medications canagliflozin (CAN) and metformin (MET) on the levels of cortical neurotransmitters in a diabetic rat model. MATERIALS AND METHODS: The rats were assigned to the control (C) group, the diabetic group that did not receive treatment (D) or the diabetic group treated with either CAN (10 mg/kg) or MET (100 mg/kg) for 2 or 4 weeks. Blood and urine glucose levels and cortical acetylcholinesterase (AChE) activity were assayed, and amino acid and monoamine levels were measured using HPLC. RESULTS: The diabetic group exhibited a significant increase in AChE activity and a decrease in monoamine and amino acid neurotransmitter levels. In the CAN group, AChE was significantly lower than that in the D and D + MET groups after 2 weeks of treatment. In addition, a significant increase in some cortical monoamines and amino acids was observed in the D + MET and D + CAN groups compared with the D group. Histopathological analysis revealed the presence of severe focal hemorrhage, neuronal degeneration, and cerebral blood vessel congestion, with gliosis in the cerebrum of rats in the D group. The CAN-treated group exhibited severe cerebral blood vessel congestion after 2 weeks of treatment and focal gliosis in the cerebrum after 4 weeks of treatment. Focal gliosis in the cerebrum of rats in the MET-treated group was observed after 2 and 4 weeks of treatment. CONCLUSIONS: We conclude that the effect of CAN and MET on neurotransmitters is potentially mediated by their antihyperglycemic and antihyperlipidemic effects. In addition, the effects of CAN on neurotransmitters might be associated with its receptor activity, and the effect of MET on neurotransmitters might be associated with cerebral metabolism.
Subject(s)
Canagliflozin/pharmacology , Cerebral Cortex/metabolism , Diabetes Mellitus, Experimental/metabolism , Metformin/pharmacology , Neurotransmitter Agents/metabolism , Acetylcholinesterase/metabolism , Amino Acids/metabolism , Animals , Biogenic Monoamines/metabolism , Blood Glucose/metabolism , Cerebral Cortex/drug effects , Cerebral Cortex/enzymology , Cerebral Cortex/pathology , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/urine , Disease Models, Animal , Glycosuria/blood , Glycosuria/complications , Glycosuria/drug therapy , Male , Rats, WistarABSTRACT
We made an attempt to evaluate/compare the cardioprotective activity of two different doses (50 and 100 mg/kg body weight, given orally for 30 consecutive days) of Egyptian sweet marjoram leaf powder (MLP) and marjoram leaf aqueous extract (MLE) against isoproterenol (ISO)-induced myocardial infarcted rats (150 mg/kg body weight, twice at an interval of 24 h on days 29 and 30). The present study showed (probably for the first time) that both MLP and MLE (especially the high dose) significantly alleviated (P < 0.05-0.001) erythrocytosis, granulocytosis, thrombocytosis, shortened clotting time, the increase in relative heart weight, myocardial oxidative stress and the leakage of heart enzymes (creatine phosphokinase (CPK), CPK-MB isoenzyme, lactate dehydrogenase and aminotransferase) in ISO-treated rats through reactivating non-enzymic (reduced glutathione) and enzymic (catalase, glutathione peroxidase, glutathione S-transferase, superoxide dismutase) antioxidant defence system and inhibiting the production of nitric oxide and lipid peroxidation in heart tissues. The modulatory effects of marjoram leaves shown in the present study were dose-dependent in most cases and much higher in MLE (4.3-20.3 % for all parameters taken together). In addition, the doses used in the present study were considered safe. In conclusion, this study may have a significant impact on myocardial infarcted patients.
Subject(s)
Cardiotonic Agents/pharmacology , Hematologic Diseases/drug therapy , Myocardial Infarction/drug therapy , Origanum/chemistry , Plant Extracts/pharmacology , Plant Leaves/chemistry , Animals , Blood Coagulation/drug effects , Cardiotonic Agents/toxicity , Disease Models, Animal , Dose-Response Relationship, Drug , Enzymes/metabolism , Heart/drug effects , Hematologic Diseases/chemically induced , Hematologic Diseases/metabolism , Isoproterenol/toxicity , Male , Myocardial Infarction/chemically induced , Myocardial Infarction/metabolism , Myocardium/enzymology , Myocardium/pathology , Oxidative Stress/drug effects , Pancytopenia/chemically induced , Pancytopenia/drug therapy , Pancytopenia/metabolism , Polycythemia/chemically induced , Polycythemia/drug therapy , Polycythemia/metabolism , Rats , Rats, Wistar , Thrombocytosis/chemically induced , Thrombocytosis/drug therapy , Thrombocytosis/metabolism , Whole Blood Coagulation TimeABSTRACT
The neuroprotective effect of Nigella sativa (NS) on amino acid neurotransmitters alteration in pentylenetetrazole (PTZ) and ciprofloxacin (CFX) treated rats in different brain regions was examined. The oral administration of NS induced an elevation in aspartate and glutamate contents, whereas the levels of GABA and glycine were decreased. Furthermore, the treated groups with PTZ and CFX caused a decrease in aspartate, glutamate and total antioxidant capacity levels, while the concentrations of GABA and glycine were increased after 14 days. Moreover, the pre- and post-treatment with NS in PTZ and CFX treated rats return the levels of these parameters near control values. So, it could be concluded that the treatment with CFX induced imbalance between the excitatory and the inhibitory amino acids which may lead to the initiation of epileptic seizures and the treatment with NS was found to ameliorate these neurological defects which reflect its potent antiepileptic activity.
Subject(s)
Amino Acids/metabolism , Anti-Bacterial Agents/toxicity , Anticonvulsants/pharmacology , Ciprofloxacin/toxicity , Epilepsy/drug therapy , Neurotransmitter Agents/metabolism , Nigella sativa/chemistry , Animals , Antioxidants/metabolism , Brain Chemistry/drug effects , Chromatography, High Pressure Liquid , Convulsants , Epilepsy/chemically induced , Epilepsy/metabolism , Male , Pentylenetetrazole , Plant Extracts/pharmacology , Rats , Valproic Acid/therapeutic useABSTRACT
The comparative preventive effect of curcumin, memantine, and diclofenac on scopolamine-induced memory dysfunction was investigated in a controlled study. A group of male and female rats was treated with one of these compounds for 15 days, after which a single dosage of scopolamine was administered. The preventive activity of curcumin on memory dysfunction was higher than that of diclofenac or memantine, that was, however, administered at lower dosages. Gender differences were observed.
Subject(s)
Curcumin/therapeutic use , Memory Disorders/prevention & control , Phytotherapy , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cholinergic Antagonists , Diclofenac/therapeutic use , Excitatory Amino Acid Antagonists/therapeutic use , Female , Male , Maze Learning/drug effects , Memantine/therapeutic use , Memory Disorders/chemically induced , Plant Extracts/therapeutic use , Rats , Scopolamine , Sex FactorsABSTRACT
This study is an extension of the previous enhancement of dissolution properties of repaglinide using liquisolid compacts. The development and validation of a highperformance liquid chromatography (HPLC) assay for the determination of repaglinide concentration in rabbit plasma for pharmacokinetic studies is described. Repaglinide optimizing formula was orally administered to rabbits and blood samples were used to determine the pharmacokinetic parameters of repaglinide, which were compared to pharmacokinetic parameters of marketed tablets (Novonorm 2 mg). Also, to investigate the biological activity of this new formula, in comparison with the commercial product, oral glucose tolerance tests (OGTT), area under the curve and insulin levels were studied. Moreover, we studied the efficacy and safety of this new formula in several potencies (0.5, 1, and 2 mg) and blood glucose, insulin, kidney and liver functions. The relative bioavailability of repaglinide from its liquisolid compact formula was found to be increased significantly in comparison to that of the marketed tablet. In regard to urea and creatinine, no significant change was recorded after the administration of the commercial and the three potencies of the new formulation compared with the control group. Similarly, in liver function tests (serum glutamic pyruvic transaminase, SGPT), there were no changes observed in its level. Regarding insulin levels, the commercial formula increased insulin levels insignificantly (3.52% change) while the new formula increased the insulin level significantly with a percent change of 37.6%. The results of the glucose tolerance test showed that the blood glucose level was decreased significantly after the commercial drug (percent change, 18.1%) while in groups treated with the new formulation the decrease was highly significant (p < 0.01) with a percent change of 29.98%. The change in area under the curve for blood glucose was significantly higher in the commercial drug plus glucose load than in the new formulation plus glucose load group (p < 0.05) in the periods of 30-45 min and 45-60 min. Furthermore, the new repaglinide formulation significantly decreased blood glucose levels more than the commercial formula.
Subject(s)
Blood Glucose/drug effects , Carbamates , Hypoglycemic Agents , Piperidines , Administration, Oral , Animals , Area Under Curve , Biological Availability , Carbamates/chemistry , Carbamates/metabolism , Carbamates/pharmacology , Chromatography, High Pressure Liquid/methods , Dosage Forms , Drug Compounding , Glucose Tolerance Test , Humans , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/metabolism , Hypoglycemic Agents/pharmacology , Insulin/blood , Male , Piperidines/chemistry , Piperidines/metabolism , Piperidines/pharmacology , Rabbits , Random Allocation , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
The study aimed to evaluate the effect Echinacea extract (E) on the testicular antioxidants function in normal rats or that subjected to anti-androgenic compound, cyproterone acetate (CA). Rats were divided into 5 groups treated daily via an oral tube for two intervals 2 and 4 weeks, 1st control, 2nd E (Echinacea treated group in dose 63 mg kg(-1)), 3rd CA (cyproterone acetate treated group in dose 25 mg kg(-1)), 4th E+CA and 5th E as prophylactic one week before E+CA treatment with the same aforementioned E or CA doses. The body, testes, epididymis and vas deferens weights were recorded. Sperm count, Nitric Oxide (NO), calcium ion (Ca2+) and malondialdhyde (MDA) contents in addition to superoxide dismutase (SOD), glutathione S-transferase (GST) activities were determined in testicular tissues. CA exhibited direct negative effect on reproductive organs weight and significant reducing effect on sperm count and Ca2+ contents. SOD and GST activities significantly decreased in addition to significant increase in NO, MDA contents reflecting the oxidative status of testis in CA treated rats. The prophylactic effect of E treatment, in time related manner, showed significant improvement in the antioxidant status of the testicular tissue which is more pronounced as compared to E+CA treatment.